The perception that intracellular lipolysis is a straightforward process that releases fatty
acids from fat stores in adipose tissue to generate energy has experienced major revisions …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

Fatty liver disease (FLD) caused by metabolic dysfunction is the leading cause of liver
disease and the prevalence is rising, especially in women. Although during reproductive …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease that encompasses a
spectrum of pathological conditions, ranging from simple steatosis (NAFL), nonalcoholic …

Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of chronic liver
disease in the Western world, probably due to the growing prevalence of obesity, metabolic …

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-
income countries and the burden of NAFLD is increasing at an alarming rate. The risk of …

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …

Hepatic fibrogenesis is a pathophysiological outcome of chronic liver injury hallmarked by
excessive accumulation of extracellular matrix proteins. Fibrosis is a dynamic process that …